The Primacy of Public Health Considerations in Defining Poor Quality Medicines

Abstract

Paul Newton and colleagues argue that public health, and not intellectual property or trade issues, should be the prime consideration in defining and combating counterfeit medicines, and that the World Health Organization (WHO) should take a more prominent role.